Slide 1: Cryo-Cell International, Inc. Schedule 14A
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A (Rule 14a-101) PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Sta
Slide 2: Presentation to ISS: Review of Performance and Shareholder Value Creation
Presentation to ISS Review of Performance and Shareholder Value Creation Ms. Mercedes Walton Mr. Anthony Finch Ms. Jill Taymans August 9, 2011
Slide 3: Forward-Looking Statements
FORWARD-LOOKING STATEMENTS Statements wherein the terms “believes”, “intends”, “projects” or “expects” as used are intended to reflect “forward-looking statements” of the Company. The information contained herein is subject to various risks, uncertainties and other factors that could cause actual re
Slide 4: Company & Industry Overview
— Ss COMPANY & INDUSTRY OVERVIEW INTERNATIONAL
Slide 5: Public Company Profile
PUBLIC COMPANY PROFILE OTC.QB CCEL Public since 1991 Shares Outstanding 11.7 million Approx. 5,000 shareholders FY’10 Annual Revenue $17.6 million Current Market Capitalization $35 million Officers Mercedes Walton, Chairman & CEO Jill Taymans, VP & Chief Financial Officer Julie Allickson, PhD, VP La
Slide 6: Business Overview
BUSINESS OVERVIEW One of the world's largest and most established cord blood stem cell banks Services U-Cord ® : Collection and cryopreservation of stem cells from umbilical cord blood Célle : Collection and preservation of stem cells from menstrual fluid (MenSC) Cryology : Cryopreservation and tran
Slide 7: U.S. Cord Blood Banking Market Dynamics
U.S. CORD BLOOD BANKING MARKET DYNAMICS Large and 4 million annual births Growing Market Target market: 800,000 to 1,000,000 annually (1) Low Penetration Rate Current annual penetration rate: less than 8.0%(2) Highly-Fragmented Approx. 25 competitors (of which two are publicly traded – PKN and CBAI)
Slide 8: Cryo-Cell Performance Highlights: FY2010
CRYO-CELL PERFORMANCE HIGHLIGHTS: FY2010 • Proven Financial Performance • Cash Flow Positive • Growing installed base • Technology License Royalties • Strong cash position • No long-term debt • Expansive IP Portfolio U-CORD® SPECIMENS PROCESSED AND STORED (CUMULATIVE)
Slide 9: Cryo-Cell Growth Drivers
CRYO-CELL GROWTH DRIVERS Established Client Base - Loyal customer base driving repeat business and client referrals Expanding Global Presence - Leveraging turnkey business model Highly Differentiated Marketing Message - Potential therapeutic applications for major diseases increasing interest and va
Slide 10: Stock Price Performance: Three Year
_— Three Year Stock Performance CCEL vs. CBAI (indexed to 100) 600 500 | 400 300 200 © 100 | 0 =e Meee eee esessssgeeeose222¢22¢22 2 ee eee SER CCERC REE R SSE EERRERARR eee eRReeRRRRE SBSSSASASTHSRSSSEASASSHESRSESSEATASSBERS ——Cryo-Cell Intemational Inc. | ——-Cord Blood America Inc. CryoCell INTERN
Slide 11: Stock Price Performance: One Year
STOCK PRICE PERFORMA One Year Stock Performance CCEL vs. CBAI (indexed to 100) i —— as Oo Oo OC OG & & & SF fe er fe fe fe fe fe fe fe fe fe fe fe SF es —~ ef fF fF fF fF Fe SF SF SF SF Fe te tc ec fe ere er tc er tc fe fe fr ete o oO oe 2 oc 82829 2 2 @& & FS o Ss SSG Pees = MPa 8 SF FASS YS 8 SB e
Slide 12: Stock Price Performance
STOCK PRICE PERFORMANCE Source: Capital IQ Note: Stem Cell/Cord Bank Index includes: (DB:V3V, NYSE:CO, AMEX:NBS, GTSM:1784, ENXTAM:CRYO, OTCBB:CBAI, ASX:CBB) and is an equal weighted Index
Slide 13: U-Cord Blood and Célle Are Complementary
U CORD BLOOD AND CÉLLE ARE COMPLEMENTARY Umbilical Cord Blood CÉLLE Therapeutic Use: Leukemia & Lymphoma, Currently in Pre-Clinical Blood disorders, trials for Diabetes, Immune diseases Cardiac disorders, Urinary incontinence & Diagnosis of endometriosis, Wound healing, Blood vessel formation, Cell
Slide 14: Research & Development Pipeline
RESEARCH & DEVELOPMENT PIPELINE Partner Indication Description Status Cryopraxis Cryobiology Ltd Urinary Incontinence & Endometrial Menstrual Stem Pre-clinical Diagnosis of endometriosis Cells (MenSCs) Snyder Wound Research Wound healing Endometrial Menstrual Stem Pre-clinical Institute Cells (MenSC
Slide 15: Financial Summary
FINANCIAL SUMMARY FY 2010 FY 2009 FY 2008 FY2007 FY2006 Revenue-processing and storage $16.1M $16.3M $17.3M $17.5M $17.2M Revenue-licensee income $1.5M $1.3M $1.0M $951K $927K Gross Profit 74.5% 74.3% 64.7% 64.2% 66.5% Net Income (Loss) $3.4M $1.6M ($741K) ($5.0M) ($2.8M) Earnings (Loss)/ Share $0.2
Slide 16: Cryo-Cell Competitive Advantages
CRYO-CELL COMPETITIVE ADVANTAGES Proprietary IP – Célle Technology Portfolio Advancing Women’s Healthcare • Isolation of the Célle menstrual stem cell offers new therapeutic potential • Future Potential Revenues – Therapeutic Commercialization Superior Quality Accreditations • FDA registered • Fully
Slide 17: Growth Strategy: Looking to the Future
Growth Strategy: Looking to the Future Organic: • Global affiliate growth • “Next Generation” services • Further diversification of service offering • Highly differentiated platform for women’s healthcare • R&D platform Strategic: • Geographical expansion • Expansion of IP portfolio • Technology lic
Slide 18: The Future is Bright
The Future is Bright To summarize, Cryo-Cell has: Over 235,000 clients worldwide 24 global license affiliates Célle, the world's only menstrual stem cell service An expansive intellectual property portfolio of proprietary menstrual stem cell technology Strategic partnerships with globally renowned s
Slide 19: Proxy Contest
PROXY CONTEST
Slide 20: The Portnoy Group
THE PORTNOY GROUP David Portnoy is seeking 5 of 6 director seats Portnoy is effectively seeking to take control of Cryo-Cell without paying a control premium to shareholders Portnoy rejected the Company’s offer of one seat (which is proportionate to his group’s ownership of Cryo-Cell) The Portnoy Gr
Slide 21: Strong Corporate Governance Principles
STRONG CORPORATE GOVERNANCE PRINCIPLES The Company has an annually elected board; all but CEO are independent Cryo-Cell has an independent lead director The Audit, Compensation, and Nominating & Governance Committees are comprised solely of independent directors The Company does not have a poison pi
Slide 22: Our Nominees
OUR NOMINEES Scott Christian -- more than 30 years of financial management experience with companies such as Automatic Data Processing, Ceridian Corporation, Norstan, Spanlink Communications and XATA, in successively expanded roles from Senior Vice President of Finance through Chief Financial Office
Slide 23: Our Nominees
OUR NOMINEES Anthony P. Finch -- 35 years of experience in cell separation and cryopreservation of cellular products. Currently serves as Chief Scientific Officer of the Irish National Blood Centre and National Tissue Typing Reference Laboratory. Has over 20 years experience in cord blood processing
Slide 24: Our Nominees
OUR NOMINEES Anthony Atala, M.D., -- 25 years of professional experience and globally recognized stem cell researcher in the area of regenerative medicine. Current work focuses on growing new human cells, tissues and organs. Serves as Director of the Wake Forest Institute for Regenerative Medicine w
Slide 25: Portnoy's Nominees
PORTNOY’S NOMINEES In sharp contrast to the Cryo-Cell Board nominated slate, the Portnoy Group’s nominees have no relevant indicated experience in the stem cell preservation industry, business of regenerative science or relevant public company operating experience. The Portnoy Group consists of a ha
Slide 26: Portnoy's Slate Is Not Qualified to Serve Cryo-Cell Shareholders
PORTNOY’S SLATE IS NOT QUALIFIED TO SERVE CRYO-CELL SHAREHOLDERS Portnoy’s Slate Brings: No Insight No Business Plan No Strategy No Track Record No relevant indicated experience in the stem cell preservation industry No relevant indicated experience in the business of regenerative science No relevan
Slide 27: Cryo-Cell International
oCell INTERNATIONA